GSK Study Shows Long-Acting HIV Shot as Effective as Daily Pill

Published on February 22, 2023

Imagine you have two superheroes battling it out for the title of Best Anti-HIV Treatment. On one side, we have GSK’s long-acting HIV injection, and on the other side, we have Gilead Sciences Inc.’s daily pill. They finally decided to settle this in the ultimate ‘head to-head’ clinical study. And guess what? The results are in! GSK’s injection showed that it can stand toe-to-toe with Gilead’s pill in terms of effectiveness. It’s like watching two fierce rivals fighting for victory, but in this case, both options are winners! This means that HIV patients now have a choice between a convenient daily pill or a longer-lasting injection. Talk about having superpowers against the virus! To top it off, this study was conducted by GSK’s HIV treatment division, ViiV Healthcare, so you know they have the expertise. Exciting stuff indeed! If you want to dive deeper into the nitty-gritty details of this ‘head to-head’ showdown, make sure to check out the published data from GSK’s ViiV Healthcare.

British drugmaker GSK’s HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc. GSK’s ViiV ran the so-called “head to-head” clinical study on its…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>